BioCentury | Aug 18, 2008
Company News

Lipid Sciences infectious, cardiovascular news

...Lipid's lead candidate is LSI-518P, an HDL mimetic peptide, in preclinical testing to treat atherosclerosis. Lipid Sciences Inc....
BioCentury | Mar 24, 2008
Clinical News

Lipid Sciences preclinical data

...20% (p=0.106) and 32% (p=0.01) after 4 and 8 weeks of treatment, respectively, vs. placebo. Lipid Sciences Inc....
BioCentury | Mar 10, 2008
Company News

Amarin, Scarista Ltd. deal

The companies expanded a 2004 deal to give Amarin an exclusive, worldwide license to develop and commercialize Scarista's IP portfolio in lipid science across all therapeutic areas. The original deal provided Amarin rights to the...
BioCentury | Feb 4, 2008
Clinical News

Lipid Sciences preclinical data

...viral load reductions of >90%. The other 6 animals in the 22-month study received placebo. Lipid Sciences Inc....
BioCentury | Dec 24, 2007
Clinical News

HDL Therapy: Completed Phase I enrollment

...LIPD completed enrollment of 28 patients in a single-blind, placebo-controlled, U.S. Phase I trial. Lipid Sciences Inc. (LIPD...
BioCentury | Oct 8, 2007
Clinical News

Lipid Sciences preclinical data

...Data were presented at the International Symposium on Drugs Affecting Lipid Metabolism in New York. Lipid Sciences Inc....
BioCentury | Apr 23, 2007
Company News

Lipid Sciences, Children’s Hospital of Philadelphia deal

...technology to develop preclinical HDL mimetic peptides for cardiovascular indications. Financial terms were not disclosed. Lipid Sciences Inc....
BioCentury | Feb 19, 2007
Company News

Lipid Sciences scientific advisory board update

Lipid Sciences Inc. (LIPD), Pleasanton, Calif. Business: Infectious, Cardiovascular Appointed: Philip Barter, director of the Heart Research Institute and a professor of medicine at the University of Sydney; and John Kastelein, a professor of medicine...
BioCentury | Jun 5, 2006
Clinical News

HDL Therapy: Pilot trial started

...untreated (placebo) plasma. The trial is expected to conclude by the end of this year. Lipid Sciences Inc....
BioCentury | May 22, 2006
Company News

Lipid Sciences board of directors update

Lipid Sciences Inc. (LIPD), Pleasanton, Calif. Business: Infectious, Cardiovascular Appointed: John Crawford, CFO and chief administrative officer at Cabrellis Pharmaceuticals Corp. WIR Staff Cardiovascular Infectious...
Items per page:
1 - 10 of 39
BioCentury | Aug 18, 2008
Company News

Lipid Sciences infectious, cardiovascular news

...Lipid's lead candidate is LSI-518P, an HDL mimetic peptide, in preclinical testing to treat atherosclerosis. Lipid Sciences Inc....
BioCentury | Mar 24, 2008
Clinical News

Lipid Sciences preclinical data

...20% (p=0.106) and 32% (p=0.01) after 4 and 8 weeks of treatment, respectively, vs. placebo. Lipid Sciences Inc....
BioCentury | Mar 10, 2008
Company News

Amarin, Scarista Ltd. deal

The companies expanded a 2004 deal to give Amarin an exclusive, worldwide license to develop and commercialize Scarista's IP portfolio in lipid science across all therapeutic areas. The original deal provided Amarin rights to the...
BioCentury | Feb 4, 2008
Clinical News

Lipid Sciences preclinical data

...viral load reductions of >90%. The other 6 animals in the 22-month study received placebo. Lipid Sciences Inc....
BioCentury | Dec 24, 2007
Clinical News

HDL Therapy: Completed Phase I enrollment

...LIPD completed enrollment of 28 patients in a single-blind, placebo-controlled, U.S. Phase I trial. Lipid Sciences Inc. (LIPD...
BioCentury | Oct 8, 2007
Clinical News

Lipid Sciences preclinical data

...Data were presented at the International Symposium on Drugs Affecting Lipid Metabolism in New York. Lipid Sciences Inc....
BioCentury | Apr 23, 2007
Company News

Lipid Sciences, Children’s Hospital of Philadelphia deal

...technology to develop preclinical HDL mimetic peptides for cardiovascular indications. Financial terms were not disclosed. Lipid Sciences Inc....
BioCentury | Feb 19, 2007
Company News

Lipid Sciences scientific advisory board update

Lipid Sciences Inc. (LIPD), Pleasanton, Calif. Business: Infectious, Cardiovascular Appointed: Philip Barter, director of the Heart Research Institute and a professor of medicine at the University of Sydney; and John Kastelein, a professor of medicine...
BioCentury | Jun 5, 2006
Clinical News

HDL Therapy: Pilot trial started

...untreated (placebo) plasma. The trial is expected to conclude by the end of this year. Lipid Sciences Inc....
BioCentury | May 22, 2006
Company News

Lipid Sciences board of directors update

Lipid Sciences Inc. (LIPD), Pleasanton, Calif. Business: Infectious, Cardiovascular Appointed: John Crawford, CFO and chief administrative officer at Cabrellis Pharmaceuticals Corp. WIR Staff Cardiovascular Infectious...
Items per page:
1 - 10 of 39